Marketwire
Marketwire, News, Syndication »
Bio-Matrix Scientific Group’s Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual Property |  |
|
Posted by Mary Canady June 7th, 2012 .
| |
| No Comments |
SAN DIEGO, CA–(Marketwire – Jun 7, 2012) – Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today that its wholly owned subsidiary Regen BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPh…
More...Marketwire, News, Syndication »
Bio-Matrix’ Regen BioPharma Unit Establishes Scientific Advisory Board and Research Relationship With Clinartis in Anticipation of Beginning Clinical Development Stem Cell Studies | |
|
Posted by Mary Canady June 6th, 2012 .
| |
| No Comments |
SAN DIEGO, CA–(Marketwire – Jun 6, 2012) –
World renowned experts to accelerate development of stem cell therapeutics
Regen anticipates new relationship with Clinartis to fast track clinical studies
…
Marketwire, News, Syndication »
Ardea Biosciences Announces Expiration of HSR Waiting Period in Connection With Proposed Merger | |
|
Posted by Mary Canady June 5th, 2012 .
| |
| No Comments |
SAN DIEGO, CA–(Marketwire – Jun 5, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) (“Ardea”), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today announced the expiration of …
More...Marketwire, News, Syndication »
Medistem Achieves Important ERC Stem Cell Clinical Trial Milestone | |
|
Posted by Mary Canady June 4th, 2012 .
| |
| No Comments |
SAN DIEGO, CA–(Marketwire – Jun 4, 2012) – Medistem Inc. (PINKSHEETS: MEDS) announced today positive safety data from the first 5 patients enrolled in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DE…
More...Marketwire, News, Syndication »
Quidel to Present at Upcoming Conferences | |
|
Posted by Mary Canady May 31st, 2012 .
| |
| No Comments |
SAN DIEGO, CA–(Marketwire – May 31, 2012) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, announced today that it will present at the following upcoming conferences:
…
Marketwire, News, Syndication »
Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers | |
|
Posted by Mary Canady May 31st, 2012 .
| |
| No Comments |
SAN DIEGO, CA–(Marketwire – May 31, 2012) – Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion d…
More...Marketwire, News, Syndication »
La Jolla Pharmaceutical Announces Issuance of U.S. Patent Covering Modified Pectin Compositions | |
|
Posted by Mary Canady May 31st, 2012 .
| |
| No Comments |
SAN DIEGO, CA–(Marketwire – May 31, 2012) – La Jolla Pharmaceutical Company (OTCQB: LJPC) (PINKSHEETS: LJPC) (the “Company” and “La Jolla”) announced today that the United States Patent and Trademark Office (USPTO) has issued patent number 8,187,642…
More...Marketwire, News, Syndication »
NuVasive to Participate in Investor Events in June 2012 | |
|
Posted by Mary Canady May 30th, 2012 .
| |
| No Comments |
SAN DIEGO, CA–(Marketwire – May 30, 2012) – NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that the Company will participate in seve…
More...Marketwire, News, Syndication »
Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, Its Oncolytic Virus Lead Product Candidate | |
|
Posted by Mary Canady May 30th, 2012 .
| |
| No Comments |
SAN DIEGO, CA–(Marketwire – May 30, 2012) – Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion …
More...Marketwire, News, Syndication »
Ardea Biosciences Earns Milestone From Bayer HealthCare | |
|
Posted by Mary Canady May 30th, 2012 .
| |
| No Comments |
SAN DIEGO, CA–(Marketwire – May 30, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it has earned a $7.5 million milestone from Bayer HealthCare (Bayer) under the terms of their April 2009 global license agreement to develop and…
More...
